SABCS 2024: General Session 2

Описание: This session took place at 9 a.m. Thursday, Dec. 12.

0:00 Introduction from moderators Michael Gnant, Medical University of Vienna, Vienna, Austria; and Zhi-Ming Shao, Fudan University Shanghai Cancer Center, Shanghai, China
00:57 Icro Meattini, University of Florence, Florence, Italy. "Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial."
11:30 Q&A
15:58 Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina. "Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial."
26:20 Q&A
31:47 Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland. "Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators."
41:03 Q&A
48:25 Elinor Sawyer, King’s College London, London, United Kingdom, discussing the results of the three previous presentations.
1:02:55 Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina. "Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)."
1:14:49 Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts. "Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)."
1:25:35 Q&A about both COMET related presentations
1:33:30 Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany. "No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial."
1:44:30 Q&A
1:48:30 Puneet Singh, MD Anderson Cancer Center, Houston, Texas, discussing the results of the three previous sessions.
2:04:25 Hongchao Pan, University of Oxford, Oxford, United Kingdom. "Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database."
2:13:45 Q&A
2:17:28 Mikael Eriksson, Karolinska Institutet, Solna, Sweden. "A long-term image-derived AI risk model for primary prevention of breast cancer."
2:32:30 Q&A
2:34::02 Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York. "APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer."
2:45:40 Q&A
2:48:00 Otto Metzger, Dana Farber Cancer Institute, Boston, Massachusetts. "AFT-38 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast Cancer."
2:59:18 Q&A
3:01:51 Sara Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington. "Beyond proof of concept: evidence to support use of CDK4/6i for HER, too"